News | May 11, 2021
Vivimed Labs to manufacture, market Favipiravir tablets
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The facility is expected to be completed in 2024
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
The production capacity is now ramped up to 90 lakh vials per month whereas earlier it was 40 lakh vials/month
These media reports are based on incorrect facts and are without any basis.
The country has constantly worked with the spirit of public-private partnership
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
Subscribe To Our Newsletter & Stay Updated
